guanidine

Small moleculeapproved

Approved

Oct 2, 1939

Guanidine is a small basic compound. Guanidine stimulates the neuromuscular junction presynaptically by inhibiting voltage-gated potassium (Kv) channels, leading to the enhanced release of acetylcholine in the synaptic cleft. This stimulatory effect of guanidine underlies its use in the therapy for the neuromuscular diseases. The hydrochloride salt of guanidine was approved by FDA for the reduction of the symptoms of muscle weakness and easy fatigability associated with the myasthenic syndrome of Eaton-Lambert. — NCATS

Clinical trial activity

0 trials · 0 clinical orgs · 2 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0

Timeline

1930s

  1. Oct 2, 1939

    Schering-Plough — Earliest FDA Approval

  2. Oct 2, 1939

    Schering-Plough — NDA Organization

  3. Oct 2, 1939

    Merck — NDA Secondary Org

Indications

Mechanism of action

Approval history

  • approvedOct 2, 1939

Chemistry & pharmacology

Loading structure…

SMILES

N=C(N)N
Mol. weight
59.07 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Discontinued

Oral

Yes

Parenteral

No

Topical

No

Sources

Also known as

  • aminoformamidine
  • aminomethanamidine
  • aminomethanamidine
  • carbamamidine
  • gu
  • gu
  • guanidin
  • guanidin
  • guanidin
  • guanidine
  • guanidine
  • guanidine
  • guanidine
  • guanidine
  • guanidine
  • guanidine
  • guanidine
  • guanidine hcl
  • guanidine hcl
  • guanidine hcl
  • guanidine hydrochloride
  • guanidine hydrochloride
  • guanidine hydrochloride
  • guanidine hydrochloride
  • guanidine hydrochloride
  • h2n-c(=nh)-nh2
  • h2n-c(=nh)-nh2
  • imidourea
  • imidourea
  • iminourea
  • iminourea
  • iminourea

Organizations

Marketing (2)

OrganizationOrg typeRelationshipDate
MerckFor profitNDA2Oct 2, 1939
Schering-PloughFor profitNDAOct 2, 1939